Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

被引:13
作者
Tosch, C.
Geist, M.
Ledoux, C.
Ziller-Remi, C.
Paul, S.
Erbs, P.
Corvaia, N. [2 ]
Von Hoegen, P. [3 ]
Balloul, J-M
Haegel, H. [1 ]
机构
[1] Transgene SA, Immunopharmacol, Dept Mol Immunol, F-67082 Strasbourg, France
[2] Ctr Immunol Pierre Fabre, St Julien En Genevoix, France
[3] Euraccine, Lasne, Belgium
关键词
pathogen-associated molecular pattern; adenoviral vector; cancer immunotherapy; NEWCASTLE-DISEASE VIRUS; IMMATURE MYELOID CELLS; HUMAN DENDRITIC CELLS; TOLL-LIKE RECEPTOR-5; PROTEIN-A OMPA; T-CELLS; BACTERIAL FLAGELLIN; ANTIGEN; VACCINATION; ACTIVATION;
D O I
10.1038/cgt.2008.85
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The delivery of stimulatory signals to dendritic cells (DCs) in the tumor microenvironment could be an effective means to break tumor-induced tolerance. The work presented here evaluates the immunostimulatory properties of pathogen-associated molecular patterns (PAMPs), microbial molecules which bind Toll-like receptors and deliver activating signals to immune cells, when expressed in tumor cells using adenoviral (Ad) vectors. In vitro, transduction of A549 tumor cells with Ad vectors expressing either flagellin from Listeria monocytogenes or P40 protein from Klebsiella pneumoniae induced the maturation of human monocyte-derived DCs in co-cultures. In mixed lymphocyte reactions (MLRs), Ad-flagellin and Ad-P40 transduction of tumor cells stimulated lymphocyte proliferation and the secretion of IFN-gamma. In vivo, these vectors were used either as stand-alone immunoadjuvants injected intratumorally or as vaccine adjuvants combined with a tumor antigen-expressing vector. When Ad-PAMPs were administered intratumorally to mice bearing subcutaneous syngeneic B16F0-CAR (cocksackie-adenovirus receptor) melanomas, tumor progression was transiently inhibited by Ad-P40. In a therapeutic vaccine setting, the combination of Ad-MUC1 and Ad-PAMP vectors injected subcutaneously delayed the growth of implanted RenCa-MUC1 tumors and improved tumor rejection when compared with vaccination with Ad-MUC1 alone. These results suggest that Ad-PAMPs could be effective immunoadjuvants for cancer immunotherapy.
引用
收藏
页码:310 / 319
页数:10
相关论文
共 43 条
[21]   Immature myeloid cells and cancer-associated immune suppression [J].
Kusmartsev, S ;
Gabrilovich, DI .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (06) :293-298
[22]   In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted [J].
Lusky, M ;
Christ, M ;
Rittner, K ;
Dieterle, A ;
Dreyer, D ;
Mourot, B ;
Schultz, H ;
Stoeckel, F ;
Pavirani, A ;
Mehtali, M .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2022-2032
[23]   Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? [J].
Lutz, MB ;
Schuler, G .
TRENDS IN IMMUNOLOGY, 2002, 23 (09) :445-449
[24]   T-cell anergy [J].
Macián, F ;
Im, SH ;
García-Cózar, J ;
Rao, A .
CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (02) :209-216
[25]   The danger model: A renewed sense of self [J].
Matzinger, P .
SCIENCE, 2002, 296 (5566) :301-305
[26]   The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells [J].
Means, TK ;
Hayashi, F ;
Smith, KD ;
Aderem, A ;
Luster, AD .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :5165-5175
[27]   Cancer vaccine design: A novel bacterial adjuvant for peptide-specific CTL induction [J].
Miconnet, I ;
Coste, I ;
Beermann, F ;
Haeuw, JF ;
Cerottini, JC ;
Bonnefoy, JY ;
Romero, P ;
Renno, T .
JOURNAL OF IMMUNOLOGY, 2001, 166 (07) :4612-4619
[28]   Functional dichotomy in CD40 reciprocally regulates effector T cell functions [J].
Murugaiyan, Gopal ;
Agrawal, Reena ;
Mishra, Gyan C. ;
Mitra, Debashis ;
Saha, Bhaskar .
JOURNAL OF IMMUNOLOGY, 2006, 177 (10) :6642-6649
[29]   TLR3-induced activation of mast cells modulates CD81 T-cell recruitment [J].
Orinska, Z ;
Bulanova, E ;
Budagian, V ;
Metz, M ;
Maurer, M ;
Bulfone-Paus, S .
BLOOD, 2005, 106 (03) :978-987
[30]   Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection [J].
Preynat-Seauve, O ;
Schuler, P ;
Contassot, E ;
Beermann, F ;
Huard, B ;
French, LE .
JOURNAL OF IMMUNOLOGY, 2006, 176 (01) :61-67